Formulary Search

You are here : Home > Formulary Search

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Return to the search options.

A-Z of Drugs : A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

A-Z of Drugs

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Search Results : Alzheimers disease (Lecanemab - Alzheimers disease)

Records returned : 4 (on 16 Jul 2025 at 23:18:44). Return to search results for ' Alzheimers disease '.

Show Icon and Status Keys Hide Icon and Status Keys

Icon Key

NFD1

Non formulary

NFD2

Not assessed for formulary status. Apply to APC / DTC before use.

Controlled drug. Prescribing and/or storage requirements may apply

Restrictions apply

Safety Alert

Unlicensed - no UK marketing license in place

Off Label

Not licensed for this indication.

NHSE

Treatment commissioned by NHS England

CDF

Cancer Drugs Fund

ICB

Treatment commissioned by the ICB

BlueTeq form to be completed

NICE

Link to the NICE website

Low carbon device

SPC

View the treatment summary for {padindicationname} on https://www.medicines.org.uk

Status Key

Red

Specialist ONLY drugs - treatment initiated and continued by specialist clinicians

Amber

Prescribing initiated and stabilised by specialist but has potential to transfer to primary care under a formal shared care agreement

Green

GPs (or non-medical prescribers in primary care) are able to take full responsibility for initiation and continuation of prescribing.

Green (see narrative)

GPs (or non-medical prescribers in primary care) are able to take full responsibility for initiation and continuation of prescribing. Please refer to the narrative on the Drug Profile page where additional information may be conveyed as to the place in therapy or restrictions for use that have been locally agreed.

Non Formulary

Not recommended for use in any health setting across the Surrey Heartlands Integrated Care System

Blue

Prescribing initiated and stabilised by specialist but has potential to transfer to primary care WITHOUT a formal shared care agreement. Please note that in some circumstances a specialist may recommend that prescribing can be started in primary care.

See narrative

See narrative - may be applied in instances where a traffic light status has not yet been agreed but an entry to the formulary has been made to clarify interim arrangements.

Drug

Indication

Status

Restrictions/Comments

Formulary Status

Links

1. Lecanemab

Drug:

Lecanemab

Indication :

Alzheimers disease

Status :

See narrative

Formulations :

Intravenous infusion

Restrictions / Comments:

Important

Important safety information - see narrative by clicking on the drug name

Lecanemab used in Alzheimer’s disease is currently not available in the NHS. Eisai (the manufacturer and market authorisation holder for lecanemab (Leqembi®)) has started to make the drug available for patients to access through independent sector clinics.

The information from NHSE here provides advice for clinical teams who may be asked to support referrals for private treatment or otherwise assess, advise and possibly treat a small number of patients who could present with potential adverse treatment effects, including symptomatic Amyloid-Related Imaging Abnormalities (ARIA).

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

NFD2

SPC

2. Souvenaid

Drug:

Souvenaid

(Milkshake style ONS)

Indication :

Alzheimers disease

Status :

Non Formulary

Formulations :

Liquid

Restrictions / Comments:

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

3. Melatonin

Drug:

Melatonin

Indication :

Alzheimers disease

Status :

Non Formulary

Formulations :

Not Specified

Restrictions / Comments:

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

NFD1

NICE

SPC

4. Donanemab

Drug:

Donanemab

Indication :

Alzheimers disease

Status :

See narrative

Formulations :

Intravenous infusion

Restrictions / Comments:

Important

This drug has not yet been assessed for formulary status.
If a patient is accessing non-NHS supplies of this medication, refer to the NHSE information here (for a similar drug called lecanemab) which provides advice on potential adverse effects.

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

NFD2

SPC